Dana Ascherman, MD
Rheumatology · Miami, FLNPI 1720050123
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,615 of the $18,401 with a category attached, or 84.9%. 5 manufacturers reported payments, led by Boehringer Ingelheim at 54.0% of the total.
Across 27 payments — averaging $681.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$10K
- E.r. Squibb & Sons, L.L.C.$6K
- EMD Serono, Inc.$1K
- Biogen$870
- Sandoz$12
Across 11 payments — averaging $43,001 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mallinckrodt Hospital Products Inc.$146K
- Teva Pharmaceuticals USA, Inc.$141K
- Boehringer Ingelheim$125K
- Novartis$26K
- Vertex$19K
- Navidea Biopharmaceuticals, Inc.$17K
What the payments were for
- Consulting fees$15,61585%
- Travel & lodging$2,15712%
- Food & beverage$6173%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 14 | $9,936 |
| E.r. Squibb & Sons, L.L.C. | 10 | $6,458 |
| EMD Serono, Inc. | 1 | $1,125 |
| Biogen | 1 | $870 |
| Sandoz | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORENCIA$6,253
How this compares
$18,401 in reported general payments places this provider in the 75th percentile of 453 rheumatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XeljanzTofacitinib Citrate | 26 | $191,828 |
| Enbrel SureclickEtanercept | 21 | $151,662 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 18 | $117,122 |
| Actemra ActpenTocilizumab | 18 | $86,447 |
| Taltz AutoinjectorIxekizumab | 12 | $80,416 |
| Mycophenolate Mofetil | 49 | $6,190 |
| Hydroxychloroquine Sulfate | 152 | $4,919 |
| MethotrexateMethotrexate Sodium | 53 | $1,696 |
| Celecoxib | 59 | $1,249 |
| Colchicine | 29 | $957 |
| Sulfasalazine | 26 | $683 |
| Gabapentin | 37 | $509 |
| Leflunomide | 17 | $466 |
| Prednisone | 60 | $383 |
| Tramadol Hcl | 35 | $207 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Miami
- Michael WeitzMiami$658K
- Joseph la ContiMiami$345K
- Robert HoffmanMiami$241K
- Christopher MesaMiami$198K
- George MunozMiami$147K
- Santiago de SoloMiami$98K
- Carlos LozadaMiami$97K
- Reuven BrombergMiami$78K
- Jeffrey RitterMiami$39K
- Alvin WellsDestin$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.